4-[1-(t-butoxycarbonyl)piperidin-4-yloxy]-3-chloroaniline | 337519-87-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-[1-(t-butoxycarbonyl)piperidin-4-yloxy]-3-chloroaniline
• 英文别名: tert-butyl 4-(4-amino-2-chlorophenoxy)piperidine-1-carboxylate
• CAS: 337519-87-6
• 化学式: C₁₆H₂₃ClN₂O₃
• 分子量: 326.823
• InChiKey: MLGKVRPDUBDRJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  64.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-[1-(t-butoxycarbonyl)piperidin-4-yloxy]-3-chloroaniline 、 (氯磺酰基)乙酸乙酯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 生成 ethyl N-[4-(1-t-butoxycarbonylpiperidin-4-yloxy)-3-chlorophenyl]sulfamoylacetate
  参考文献：
  名称：

  Cinnamyl Derivatives: Synthesis and Factor Xa (FXa) Inhibitory Activities

  摘要：

  为了开发一种强效且可通过口服给药的抗凝剂，合成了一系列含有肉桂基部分的化合物，并检测了它们对因子Xa (FXa)的抑制活性。结果显示，一些肉桂基衍生物具有强效的FXa体外抑制活性。在这些化合物中，含有取代基位于中心苯环3-位的化合物，如(N-{4-[1-(乙酰亚胺基)哌啶-4-氧基]-3-氯苯基}-N-[(E)-3-(3-氨基苯基)-2-丙烯基]磺酰胺)乙酸二盐酸盐(45b)和(N-{4-[1-(乙酰亚胺基)哌啶-4-氧基]-3-羧酰胺苯基}-N-[(E)-3-(3-氨基苯基)-2-丙烯基]磺酰胺)乙酸二盐酸盐(45j)，表现出强效的FXa抑制活性，其IC50值在体外小于10 nM。这些化合物在体外和体外实验中均显示出强效的抗凝活性。此外，这些化合物没有致命毒性(30 mg/kg，静脉注射)。

  DOI：

  10.1248/cpb.56.758
• 作为产物：
  描述：

  tert-butyl 4-(2-chloro-4-nitro)phenoxypiperidine-1-caroxylate 在 锌 作用下， 以 溶剂黄146 为溶剂， 反应 2.0h， 以90%的产率得到4-[1-(t-butoxycarbonyl)piperidin-4-yloxy]-3-chloroaniline
  参考文献：
  名称：

  Cinnamyl Derivatives: Synthesis and Factor Xa (FXa) Inhibitory Activities

  摘要：

  为了开发一种强效且可通过口服给药的抗凝剂，合成了一系列含有肉桂基部分的化合物，并检测了它们对因子Xa (FXa)的抑制活性。结果显示，一些肉桂基衍生物具有强效的FXa体外抑制活性。在这些化合物中，含有取代基位于中心苯环3-位的化合物，如(N-{4-[1-(乙酰亚胺基)哌啶-4-氧基]-3-氯苯基}-N-[(E)-3-(3-氨基苯基)-2-丙烯基]磺酰胺)乙酸二盐酸盐(45b)和(N-{4-[1-(乙酰亚胺基)哌啶-4-氧基]-3-羧酰胺苯基}-N-[(E)-3-(3-氨基苯基)-2-丙烯基]磺酰胺)乙酸二盐酸盐(45j)，表现出强效的FXa抑制活性，其IC50值在体外小于10 nM。这些化合物在体外和体外实验中均显示出强效的抗凝活性。此外，这些化合物没有致命毒性(30 mg/kg，静脉注射)。

  DOI：

  10.1248/cpb.56.758

文献信息

• Benzamidine derivatives
  申请人：Sankyo Company, Limited

  公开号：US06555556B1

  公开（公告）日：2003-04-29

  Benzamidine derivatives of formula (I) or pharmaceutically acceptable salts thereof exhibit excellent inhibitory activity against factor Xa and are useful for treating or preventing blood coagulation disorders: wherein R1 represents a hydrogen atom, a halogen atom, an alkyl group or a hydroxyl group; R2 represents a hydrogen atom, a halogen atom or an alkyl group, R3 represents a hydrogen atom, an optionally substituted alkyl group, an aralkyl group, an optionally substituted alkanoyl group or an optionally substituted alkylsulfonyl group, R4 and R5 are the same as or different from each other and each represent a hydrogen atom, a halogen atom, an optionally substituted alkyl group, an alkoxy group, a carboxyl group, an alkoxycarbonyl group or an optionally substituted carbamoyl group, and R6 represents a substituted pyrrolidine group or substituted piperidine group.

  Benzamidine衍生物的化学式(I)或其药学上可接受的盐对Xa因子表现出优异的抑制活性，并且可用于治疗或预防血液凝固紊乱：其中R1代表氢原子、卤素原子、烷基或羟基；R2代表氢原子、卤素原子或烷基，R3代表氢原子、可选择取代的烷基、芳基烷基、可选择取代的烷酰基或可选择取代的烷基磺酰基，R4和R5彼此相同或不同，各自代表氢原子、卤素原子、可选择取代的烷基、烷氧基、羧基、烷氧羰基或可选择取代的氨基羰基，R6代表取代的吡咯烷基或取代的哌啶基。
• Fused Heterocyclic Compound
  申请人：Ishikawa Tomoyasu

  公开号：US20070244132A1

  公开（公告）日：2007-10-18

  The present invention relates to a compound represented by the formula: wherein W is C(R 1 ) or N, each A is an optionally substituted aryl group or a heteroaryl group, X 1 is —NR 3 —Y 1 —, —O—, —S—, —SO—, —SO 2 — or —CHR 3 — wherein R 3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R 3 is optionally bonded to A to form an optionally substituted ring structure, R 1 is a hydrogen atom or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom, R 2 is a hydrogen atom or optionally substituted group bonded via a carbon atom or a sulfur atom, or R 1 and R 2 , or R 2 and R 3 are optionally bonded to form an optionally substituted ring structure, or a salt thereof, and a tyrosine kinase inhibitor or an agent for the prophylaxis or treatment of cancer, which contains this compound or a prodrug thereof.

  本发明涉及一种化合物，其表示式为：其中W是C（R1）或N，每个A是可选取代的芳基或杂环基，X1是—NR3—Y1—、—O—、—S—、—SO—、—SO2—或—CHR3—，其中R3是氢原子或可选取代的脂肪烃基，或者R3与A可选地结合形成可选取代的环状结构，R1是氢原子或通过碳原子、氮原子或氧原子键合的可选取代基团，R2是氢原子或通过碳原子或硫原子键合的可选取代基团，或者R1和R2，或者R2和R3可选地键合形成可选取代的环状结构，或其盐，以及含有该化合物或其前药的酪氨酸激酶抑制剂或预防或治疗癌症的药物。
• Fused heterocyclic compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07507740B2

  公开（公告）日：2009-03-24

  The present invention relates to a compound represented by the formula: wherein W is C(R1) or N, each A is an optionally substituted aryl group or a heteroaryl group, X1 is —NR3—Y1—, —O—, —S—, —SO—, —SO2— or —CHR3— wherein R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3 is optionally bonded to A to form an optionally substituted ring structure, R1 is a hydrogen atom or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom, R2 is a hydrogen atom or optionally substituted group bonded via a carbon atom or a sulfur atom, or R1 and R2, or R2 and R3 are optionally bonded to form an optionally substituted ring structure, or a salt thereof, and a tyrosine kinase inhibitor or an agent for the prophylaxis or treatment of cancer, which contains this compound or a prodrug thereof.

  本发明涉及一种由以下公式表示的化合物：其中W为C（R1）或N，每个A为可选取代的芳基或杂环基，X1为—NR3—Y1—、—O—、—S—、—SO—、—SO2—或—CHR3—，其中R3为氢原子或可选取代的脂肪烃基，或R3可选择与A结合形成可选取代的环状结构，R1为氢原子或通过碳原子、氮原子或氧原子键合的可选取代基，R2为氢原子或通过碳原子或硫原子键合的可选取代基，或R1和R2，或R2和R3可选择结合形成可选取代的环状结构，或其盐，并且包含该化合物或其前药的酪氨酸激酶抑制剂或癌症预防或治疗剂。
• FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND
  申请人：Seto Masaki

  公开号：US20100234351A1

  公开（公告）日：2010-09-16

  A compound of the formula: wherein ring A is a 7-membered or 8-membered nitrogen-containing ring optionally further substituted, ring B is an optionally substituted aryl group or an optionally substituted heteroaryl group, X 1 is a group represented by —NR 3 —Y 1 —, —O—, —S—, —SO—, —SO 2 — or —CHR 3 — wherein R 3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R 3 may be bonded to the carbon atom of ring B to form an optionally substituted ring structure, and Y 1 is a bond or an optionally substituted alkylene, R 1 is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom, the formula shows a single bond or a double bond, when R 2 is —R 2 , R 2 is a hydrogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom, and when R 2 is ═R 2 , R 2 is an oxo group, an optionally substituted alkylidene group, or an optionally substituted imino group.

  该化合物的化学式为：其中环A是一个7-或8-成员的含氮环，可选择进一步取代，环B是一个可选择取代的芳基或杂芳基，X1是一个由—NR3—Y1—、—O—、—S—、—SO—、—SO2—或—CHR3—表示的基团，其中R3是氢原子或可选择取代的脂肪烃基团，或R3可与环B的碳原子结合形成可选择取代的环结构，Y1是一个键或可选择取代的烷基，R1是氢原子或通过碳原子或硫原子结合的可选择取代的基团，化学式中显示单键或双键，当R2是—R2时，R2是氢原子或通过碳原子结合的可选择取代的基团，氮原子、氧原子或硫原子，当R2是═R2时，R2是一个氧代基团、可选择取代的烷基亚甲基基团或可选择取代的亚胺基团。
• Bi- and tricyclic fused pyrimidines as tyrosine kinase inhibitors
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US08178543B2

  公开（公告）日：2012-05-15

  The present invention relates to a compound represented by the formula: wherein W is C(R1) or N, each A is an optionally substituted aryl group or a heteroaryl group, X1 is —NR3—Y1—, —O—, —S—, —SO—, —SO2— or —CHR3— wherein R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3 is optionally bonded to A to form an optionally substituted ring structure, R1 is a hydrogen atom or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom, R2 is a hydrogen atom or optionally substituted group bonded via a carbon atom or a sulfur atom, or R1 and R2, or R2 and R3 are optionally bonded to form an optionally substituted ring structure, or a salt thereof, and a tyrosine kinase inhibitor or an agent for the prophylaxis or treatment of cancer, which contains this compound or a prodrug thereof.

  本发明涉及一种由以下式表示的化合物：其中W是C（R1）或N，每个A是一个可选地取代的芳基或杂环基，X1是-NR3-Y1-、-O-、-S-、-SO-、-SO2-或-CHR3-，其中R3是氢原子或可选地取代的脂肪烃基，或者R3可选择与A结合形成可选地取代的环结构，R1是氢原子或通过碳原子、氮原子或氧原子键合的可选地取代的基团，R2是氢原子或通过碳原子或硫原子键合的可选地取代的基团，或者R1和R2，或者R2和R3可选择结合形成可选地取代的环结构，或其盐，以及含有该化合物或其前药的酪氨酸激酶抑制剂或癌症预防或治疗剂。